Recruiting OBSERVATIONAL NCT06410976

Prospective Clinical Assessment Study in Children With Hypochondroplasia (HCH)

Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL

Sponsor: QED Therapeutics, a BridgeBio company

Updated 13 times since 2024 Last updated: Oct 8, 2025 Started: Jun 5, 2024 Primary completion: Oct 31, 2026 Completion: Oct 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Hypochondroplasia and is currently actively recruiting participants. QED Therapeutics, a BridgeBio company leads this study, which shows 13 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

13 versions recorded

Dec 2025 — Present [monthly]

Recruiting
Nov 2025 — Dec 2025 [monthly]

Recruiting
Sep 2025 — Nov 2025 [monthly]

Recruiting
Aug 2025 — Sep 2025 [monthly]

Recruiting
Jul 2025 — Aug 2025 [monthly]

Recruiting

▶ Show 8 earlier versions

Jun 2025 — Jul 2025 [monthly]

Recruiting
Feb 2025 — Jun 2025 [monthly]

Recruiting
Dec 2024 — Feb 2025 [monthly]

Recruiting
Nov 2024 — Dec 2024 [monthly]

Recruiting
Sep 2024 — Nov 2024 [monthly]

Recruiting
Aug 2024 — Sep 2024 [monthly]

Recruiting
Jul 2024 — Aug 2024 [monthly]

Recruiting
Jun 2024 — Jul 2024 [monthly]

Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

QED Therapeutics, a BridgeBio company

Data source: QED Therapeutics, a BridgeBio company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Baltimore, United States , Bergen, Norway , Bron, France , Cincinnati, United States , Coimbra, Portugal , Columbia, United States , Glasgow, United Kingdom , London, Canada , London, United Kingdom and 15 more locations